The groundbreaking event aims to address the significant funding gap faced by women entrepreneurs in healthcare and life sciences, where only three percent of venture capital funding goes to female founders, and an even smaller percentage to women of color.
A review of the latest biopharma job cuts thus far in September and beyond.
The recent success of obesity treatments, particularly Ozempic (semaglutide) and Mounjaro (tirzepatide), has driven significant interest in glucagon-like peptide-1 receptor (GLP1R) targeting drugs. These therapies have witnessed a 595% increase in licensing deal value between 2019 and 2024 year-to-date (YTD), exceeding $6.2 billion in 2024 YTD alone.
Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes was linked to an elevated rate of temporary side effects in its initial test phase on humans.
The vaccine maker last month projected sales of $3 billion and $3.5 billion for this year, which will be its lowest annual revenue since Moderna launched its COVID-19 vaccine in late 2020 – the company’s first commercial product.
The investments are part of Lilly’s ongoing commitment to expand production, especially for its top-selling diabetes and obesity drugs, Mounjaro and Zepbound, respectively.